<DOC>
	<DOCNO>NCT00314262</DOCNO>
	<brief_summary>Evaluate effect cell patient response study medication , assess side effect medication , evaluate chemical cell may tell drug work , , receive study medication .</brief_summary>
	<brief_title>Phase I/II Study Chemoprevention With EGFR COX-2 Inhibitor</brief_title>
	<detailed_description>The purpose study evaluate effect cell patient response study medication , assess side effect medication , evaluate chemical cell may tell drug work , , receive study medication . Approximately 61 patient participate Emory Winship Cancer Institute Emory Crawford W. Long Hospital Atlanta , Georgia .</detailed_description>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Participants must premalignant lesion . Lesion sit include oral cavity , oropharynx , larynx . Must least &gt; 20 packyear history smoking . Must Eastern Cooperative Oncology Group ( ECOG ) /Zubrod performance status 01 . Participants must 18 year age old . No contraindication laryngoscopy biopsy . Adequate liver function . Must hemoglobin hematocrit level low limit normal range . Participants must prothrombin time ( PT ) /partial thromboplastin time ( PTT ) level low limit normal range . Women childbearing potential must negative serum pregnancy test within 72 hour receive treatment . Must able swallow oral dose erlotinib celecoxib . Participants must disease free . Final eligibility determine health professional conduct trial . Participants acute intercurrent illness surgery within precede 4 week unless fully recover . History previous malignancy unless cancer stage I II render free disease 1 year . Pregnant breast feeding . Not practice adequate contraception participant child bear potential . Female patient positive pregnancy test . History recent myocardial infarction . Hypertension adequately control medication . Documented history coagulopathy . Documented history congestive heart failure ( CHF ) great New York Heart Association ( NYHA ) Grade II . Participants take COX2 inhibitor EGFR tyrosine kinase inhibitor within 3 month study entry . Documented history interstitial lung disease . Known connective tissue disease . History nonsteroidal antiinflammatory drug ( NSAID ) induce ulcer risk GI ulcer . Participated clinical trial investigational drug within 12 month prior enrollment . Final eligibility determine health professional conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Skin Lesions</keyword>
	<keyword>Premalignant Lesion</keyword>
</DOC>